Patients with mCRPC who have a complete or partial response or stable disease based on 68Ga-PSMA PET/CT imaging have significantly longer progression-free survival compared with treatment responses ...
“This study adjusted for testosterone levels, which can influence PSA and outcomes, and still found a significant association. This strengthens the argument that PSA response to neoadjuvant therapy is ...
The optimal time to measure PSA response to treatment is 9 months for patients with mHSPC to gauge risk for disease progression. In real-world patients with metastatic, hormone-sensitive prostate ...
PSA nadir 6 months after RT correlated with prostate cancer outcomes at 12 months and 5 years Nadir ≥0.1 ng/mL associated with worse outcomes with RT ± ADT Editorial questions relevance of findings in ...
This article was reviewed by Darragh O’Carroll, MD. Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting screened regularly for prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback